Processa Pharmaceuticals (PCSA) R&D chief buys 1,786 shares at $2.57

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and President of Research & Development David Young reported an open-market purchase of 1,786 shares of common stock at $2.57 per share on May 29, 2026. Following this transaction, he directly holds 17,131 common shares.

The filing also lists indirect holdings of common stock, including 742 shares held through CorLyst, LLC, 432 shares held through family entities, and 1,242 shares held through the Young-Plaisance Revocable Trust as of the same date.

Insider Trade Summary

Net Buyer: 1,786 shares ($4,590)

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 1,786 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,786	$2.57	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 17,131 shares (Direct, null); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust)

Footnotes (1)

Key Figures

Open-market purchase: 1,786 shares Purchase price: $2.57 per share Direct holdings after transaction: 17,131 shares +3 more

6 metrics

Open-market purchase 1,786 shares Common Stock bought on May 29, 2026

Purchase price $2.57 per share Price for 1,786-share open-market purchase

Direct holdings after transaction 17,131 shares Common Stock directly owned following purchase

Indirect holdings via CorLyst, LLC 742 shares Common Stock held indirectly

Indirect holdings via family entities 432 shares Common Stock held indirectly

Indirect holdings via revocable trust 1,242 shares Common Stock held by Young-Plaisance Revocable Trust

Key Terms

open-market purchase, indirect ownership, non-derivative, reporting person

4 terms

open-market purchase financial

"transaction_action":"open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""ownership_type":"indirect","ownership_code":"I""

non-derivative financial

""transaction_type":"non-derivative""

reporting person regulatory

""reportingPersons":[{"name":"Young David""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		P		1,786	A	$2.57	17,131	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did David Young report at Processa Pharmaceuticals (PCSA)?

David Young reported an open-market purchase of 1,786 shares of Processa Pharmaceuticals common stock. The shares were bought at $2.57 per share on May 29, 2026, increasing his directly held position reported in the filing.

At what price did David Young buy Processa Pharmaceuticals (PCSA) shares?

David Young bought Processa Pharmaceuticals common stock at $2.57 per share. The Form 4 shows an open-market purchase of 1,786 shares at this price on May 29, 2026, reflecting his latest direct acquisition activity.

How many Processa Pharmaceuticals (PCSA) shares does David Young now hold directly?

After the reported transaction, David Young directly holds 17,131 shares of Processa Pharmaceuticals common stock. This figure in the Form 4 represents his direct ownership position following the 1,786-share open-market purchase.

What indirect Processa Pharmaceuticals (PCSA) holdings are associated with David Young?

The filing lists indirect holdings of Processa Pharmaceuticals common stock: 742 shares via CorLyst, LLC, 432 shares via family entities, and 1,242 shares via the Young-Plaisance Revocable Trust. These positions are reported separately from his direct holdings.

What role does David Young hold at Processa Pharmaceuticals (PCSA)?

David Young is a director and serves as President of Research & Development at Processa Pharmaceuticals. His Form 4 filing reports both his recent open-market share purchase and various indirect ownership positions in the company’s common stock.